|
|
 Previous Article | Table of Contents | Next Article 
Blood, 15 March 2002, Vol. 99, No. 6, pp. 2245-2247
BRIEF REPORT
Campath-1H and fludarabine in combination are highly active in
refractory chronic lymphocytic leukemia
Ben Kennedy,
Andy Rawstron,
Chris Carter,
Mary Ryan,
Kevin Speed,
Guy Lucas, and
Peter Hillmen
From the Haematological Malignancy Diagnostic Service,
University of Leeds, United Kingdom; Department of Hematology,
Huddersfield Royal Infirmary, Yorkshire, United Kingdom; Department of
Hematology, Altnagelvin Area Hospital, Londonderry, Derry City,
Northern Ireland, United Kingdom; Department of Hematology, Princess of
Wales Hospital, Grimsby, United Kingdom; University Department of
Hematology, Manchester Royal Infirmary, United Kingdom.
Campath-1H (alemtuzumab) is the most effective
monoclonal antibody in single-agent use in B-cell chronic lymphocytic
leukemia (CLL) with reported response rates of 33% to 70%.
Combination therapy is now the conventional treatment for most
hematologic malignancies. Monoclonal antibody treatments may sensitize
tumor cells to subsequent chemotherapy. We report the combination of Campath-1H with fludarabine in patients with CLL refractory to each
agent used singly. Six patients who had received a median of 8 courses
of fludarabine (range, 4-10 courses) and 16 weeks of Campath-1H (range,
8-32 weeks) were treated. Five patients responded, including one who
had a complete response by National Cancer Institute criteria. The
responses observed were better in each patient than responses after
each agent used singly. Complete morphologic bone marrow responses were
seen in 3 patients, including eradication of disease measured by
sensitive flow cytometry in 2. Campath-1H combined with fludarabine is
a highly promising novel therapy for refractory CLL.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
W. G. Wierda
Treatments for Patients with Chronic Lymphocytic Leukemia
ASCO Educational Book,
January 1, 2008;
2008(1):
297 - 305.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Hillmen, A. B. Skotnicki, T. Robak, B. Jaksic, A. Dmoszynska, J. Wu, C. Sirard, and J. Mayer
Alemtuzumab Compared With Chlorambucil As First-Line Therapy for Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
December 10, 2007;
25(35):
5616 - 5623.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Montillo, A. Tedeschi, S. Miqueleiz, S. Veronese, R. Cairoli, L. Intropido, F. Ricci, A. Colosimo, B. Scarpati, M. Montagna, et al.
Alemtuzumab As Consolidation After a Response to Fludarabine Is Effective in Purging Residual Disease in Patients With Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
May 20, 2006;
24(15):
2337 - 2342.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Montserrat, C. Moreno, J. Esteve, A. Urbano-Ispizua, E. Gine, and F. Bosch
How I treat refractory CLL
Blood,
February 15, 2006;
107(4):
1276 - 1283.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. G. Wierda
Current and Investigational Therapies for Patients with CLL
Hematology,
January 1, 2006;
2006(1):
285 - 294.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Elter, P. Borchmann, H. Schulz, M. Reiser, S. Trelle, R. Schnell, M. Jensen, P. Staib, T. Schinkothe, H. Stutzer, et al.
Fludarabine in Combination With Alemtuzumab Is Effective and Feasible in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: Results of a Phase II Trial
J. Clin. Oncol.,
October 1, 2005;
23(28):
7024 - 7031.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. G. Wierda, T. J. Kipps, and M. J. Keating
Novel Immune-Based Treatment Strategies for Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
September 10, 2005;
23(26):
6325 - 6332.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Moreton, B. Kennedy, G. Lucas, M. Leach, S. M.B. Rassam, A. Haynes, J. Tighe, D. Oscier, C. Fegan, A. Rawstron, et al.
Eradication of Minimal Residual Disease in B-Cell Chronic Lymphocytic Leukemia After Alemtuzumab Therapy Is Associated With Prolonged Survival
J. Clin. Oncol.,
May 1, 2005;
23(13):
2971 - 2979.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Hallek and On Behalf Of The German CLL Study Group
Chronic Lymphocytic Leukemia (CLL): First-Line Treatment
Hematology,
January 1, 2005;
2005(1):
285 - 291.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. G. Gribben
Salvage Therapy for CLL and the Role of Stem Cell Transplantation
Hematology,
January 1, 2005;
2005(1):
292 - 298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. C. Rawstron, B. Kennedy, P. Moreton, A. J. Dickinson, M. J. Cullen, S. J. Richards, A. S. Jack, and P. Hillmen
Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia
Blood,
March 15, 2004;
103(6):
2027 - 2031.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Mavromatis and B. D. Cheson
Monoclonal Antibody Therapy of Chronic Lymphocytic Leukemia
J. Clin. Oncol.,
May 1, 2003;
21(9):
1874 - 1881.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Faderl, D. A. Thomas, S. O'Brien, G. Garcia-Manero, H. M. Kantarjian, F. J. Giles, C. Koller, A. Ferrajoli, S. Verstovsek, B. Pro, et al.
Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignancies
Blood,
May 1, 2003;
101(9):
3413 - 3415.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Keating, N. Chiorazzi, B. Messmer, R. N. Damle, S. L. Allen, K. R. Rai, M. Ferrarini, and T. J. Kipps
Biology and Treatment of Chronic Lymphocytic Leukemia
Hematology,
January 1, 2003;
2003(1):
153 - 175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. J. Keating, I. Flinn, V. Jain, J.-L. Binet, P. Hillmen, J. Byrd, M. Albitar, L. Brettman, P. Santabarbara, B. Wacker, et al.
Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study
Blood,
May 15, 2002;
99(10):
3554 - 3561.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
